NASDAQ: BMRABiomerica Inc Stock
$0.68-0.03 (-4.23%)
Updated Apr 25, 2024
BMRA Price
$0.68
Fair Value Price
N/A
Market Cap
$11.35M
52 Week Low
$0.66
52 Week High
$2.13
P/E
-1.82x
P/B
1.45x
P/S
3.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.41M
Earnings
-$6.35M
Gross Margin
11.4%
Operating Margin
-116.58%
Profit Margin
-117.5%
Debt to Equity
0.33
Operating Cash Flow
-$5M
Beta
-0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMRA Overview
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMRA is good value based on its book value relative to its share price (1.45x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
BMRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BMRA due diligence checks available for Premium users.
Be the first to know about important BMRA news, forecast changes, insider trades & much more!
BMRA News
Valuation
BMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.82x
Industry
29.73x
Market
40.97x
BMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.45x
Industry
3.71x
BMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMRA's financial health
Profit margin
Revenue
$1.0M
Net Income
-$1.9M
Profit Margin
-188.6%
BMRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BMRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.3M
Liabilities
$2.5M
Debt to equity
0.33
BMRA's short-term assets ($8.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMRA's short-term assets ($8.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$16.0k
Financing
$0.0
BMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BMRA vs Medical Device Stocks
Biomerica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.